SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001566044-20-000021
Filing Date
2020-11-05
Accepted
2020-11-05 07:12:48
Documents
16
Period of Report
2020-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mnlo-20201105.htm   iXBRL 8-K 34124
2 EX-99.1 mnlo-20201105q3xexx991.htm EX-99.1 309554
8 image1.jpg GRAPHIC 33776
  Complete submission text file 0001566044-20-000021.txt   564820

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mnlo-20201105.xsd EX-101.SCH 2547
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mnlo-20201105_cal.xml EX-101.CAL 821
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mnlo-20201105_def.xml EX-101.DEF 1785
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mnlo-20201105_lab.xml EX-101.LAB 25280
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mnlo-20201105_pre.xml EX-101.PRE 13298
9 EXTRACTED XBRL INSTANCE DOCUMENT mnlo-20201105_htm.xml XML 11687
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 201288648
SIC: 2834 Pharmaceutical Preparations